A comprehensive discussion of Notch signaling is beyond the scope of this article. Relevant review articles are quoted whenever possible and the reader is referred to them. The Notch signaling network has been known for decades to developmental biologists as a key player in cell fate determination (Greenwald, 1998; ArtavanisTsakonas et al., 1999) . NOTCH genes encode singlepass, heterodimeric transmembrane receptors that participate in communication between contiguous cells. Mature Notch receptors derive from proteolytic processing of large single polypeptide precursors that are cleaved by a furin-like protease (Logeat et al., 1998) into heterodimers comprising an extracellular subunit (N EC ) noncovalently associated with a transmembrane subunit (N TM ). N EC contains multiple EGF-like repeats, while N TM includes an extracellular stump containing three 'Lin-Notch' repeats, a single-pass transmembrane domain and an intracellular domain. This in turn includes a 'RAM23' domain, which participates in CBF-1 binding (see below), six ankyrin repeats, a polyglutamine region, and a Pro-Glu-Ser-Thr (PEST) region, which may be important for ubiquitination (Greenwald, 1998; Artavanis-Tsakonas et al., 1999) . The N EC -N TM interaction is Ca 2 þ -dependent (Rand et al., 2000) and its dissociation upon ligand binding triggers receptor activation. Four NOTCH genes are known in rodents and humans. The four mammalian Notch receptors differ in the number of EGF-like repeats and the length of the intracellular domain, while the ankyrin repeats are most conserved (Maine et al., 1995; Kortschak et al., 2001) . Notch receptors are activated by cell-membrane-associated ligands belonging to the Delta or Jagged (Serrate) families. Notch ligands are collectively known as 'DSL' from Delta (Drosophila), Serrate (Drosophila) and Lag-1 (C. Elegans). The relative affinity of Notch receptors for different ligands is controlled by glycosylation of N EC catalysed by related glycosyltransferases, Manic Fringe, Lunatic Fringe and Radical Fringe (Fortini, 2000; Moloney et al., 2000) . Fucosylation of specific Ser and Thr residues in N EC by an O-fucosyltransferase in indispensable for Notch signaling in Drosophila (Okajima and Irvine, 2002) . Ligand binding is thought to dissociate the extracellular subunit from the transmembrane subunit, causing trans-endocytosis of N EC into ligand-expressing cells (Parks et al., 2000) . Dissociation triggers a two-step proteolytic cleavage of N TM . First, the extracellular 'stump' of N TM (including three 'Lin/ Notch' repeats) is clipped by TNF-alpha converting enzyme (TACE), a metalloprotease of the a disintegrin and metalloprotease (ADAM) family (Brou et al., 2000; Mumm et al., 2000) . This makes N TM susceptible to cleavage by a presenilin-1-dependent g-secretase activity (Saxena et al., 2001) , which cleaves it within the transmembrane sequence, releasing an intracellular domain, N IC . N IC translocates to the nucleus (Lewis, 1998; Struhl and Adachi, 1998) , where it modulates gene expression primarily, although not exclusively, by binding to a ubiquitous transcription factor CBF-1 (Rbp-Jk) (Artavanis-Tsakonas et al., 1999) . This binding converts CBF-1 from a transcriptional repressor into an activator, by dissociating from it a corepressor complex including silencing mediator of retinoid and thyroid hormone receptors (SMRT) (Kao et al., 1998) , the unique corepressor CIR (Hsieh et al., 1999) and histone deacetylase 1 (HDAC-1) and recruiting instead nuclear coactivators such as SKIP (Zhou et al., 2000) and MAML1 (Mastermind in Drosophila) (Petcherski and Kimble, 2000; Wu et al., 2000) and histone acetyltransferases PCAF and GCN5 (Kurooka and Honjo, 2000) . CBF-1-independent signaling mediated by Notch accessory protein Deltex has been proposed as well Ordentlich et al., 1998; Yamamoto et al., 2001 ). Deltex has been described as both signaling downstream of Notch and necessary for Notch activation (Matsuno et al., 2002) . Notch signal strength and duration are dosage dependent and modulated at multiple levels, both extra-and intracellularly, by post-translational modifications and by various accessory proteins that control receptor recycling and membrane availability (Royet et al., 1998; Santolini et al., 2000; Zlobin et al., 2000) . Notch signaling is physiologically extinguished by ubiquitination-and proteasome-mediated degradation of N IC . Ubiquitination is catalysed by the human homolog of C. elegans SEL10 , Hect-family E3 ligase Itch (Qiu et al., 2000) and c-Cbl (Jehn et al., 2002) . Phosphorylation of intracellular Notch by GSK-3b (Foltz et al., 2002) and possibly by other, unspecified kinases (Ronchini and Capobianco, 2000; Shimizu et al., 2000; Ingles-Esteve et al., 2001 ) has been described and may contribute to regulating the half-life of Notch intracellular proteins. Notch target genes include among others helix-loop-helix inhibitory transcription factors of the hairy enhancer of split (HES) family (Enhancer of Split in Drosophila) (ArtavanisTsakonas et al., 1999) that modulate differentiation, cell cycle mediators such as p21 cip1/waf1 (Rangarajan et al., 2001b) and cyclin D1 (Ronchini and Capobianco, 2001) , as well as NF-kB family (Cheng et al., 2001 ) and PPAR family (Garces et al., 1997; Nickoloff et al., 2002) transcription factors. Putative nontranscriptional effects of Notch signaling include direct activation of NF-kB by Notch ligands and inhibition of JNK activation Zecchini et al., 1999) . From this list of targets, it is clear that Notch signaling can have multiple, pleiotropic effects on cell differentiation, proliferation and survival. Not surprisingly, Notch activation can affect virtually every aspect of cell fate determination in a context-dependent manner. Figure 1 shows a simplified representation of the main processes involved in Notch signaling and pharmacological strategies that have been used or can be used to inhibit or activate it.
The simple question 'what does Notch do in cells?' does not have an equally simple, straightforward answer. Studies in Drosophila and C. elegans development (Greenwald, 1998; Artavanis-Tsakonas et al., 1999) indicate that Notch activation regulates the ability of a cell to respond to a differentiation signal. This is often oversimplified into the blanket assumption that 'Notch prevents cell differentiation', and observations made utilizing overexpression of constitutively active Notch receptors have been often interpreted as supporting this dogma. Over the last 12 years, evidence has steadily accumulated that Notch signaling is dysregulated in several malignancies and offers a potential target for therapeutic intervenion Zlobin et al., 2000) . The first link between Notch signaling and human maliagncies was uncovered when a 9 : 7 chromosomal translocation associated with about 10% of T-cell lymphoblastic leukemias was shown to produce a truncated human Notch-1 lacking most of the extracellular subunit (Ellisen et al., 1991) . Notch receptors lacking extracellular subunits are constitutively activated (Artavanis-Tsakonas et al., 1999) . Such truncated forms of all four Notch isoforms have transforming activity in vitro (Capobianco et al., 1997) and in various animal models (Pear et al., 1996; Bellavia et al., 2000; Callahan and Raafat, 2001) . In humans, deregulated expression of wild-type Notch receptors, ligands and targets is observed in a growing number of solid tumors, including cervical, head and neck, endometrial, renal, lung and breast carcinomas, pleural mesotheliomas and malignant melanomas (Zagouras et al., 1995; Daniel et al., 1997; Dang et al., 2000; Leethanakul et al., 2000; Rae et al., 2000; Suzuki et al., 2000; Hendrix et al., 2002; Weijzen et al., 2002a; Bocchetta et al., 2003) , and hematological malignancies such as Hodgkin lymphomas, anaplastic large-cell non-Hodgkin lymphomas, and subsets of acute myeloid leukemias and B-cell chronic lymphoid leukemia (B-CLL) (Tohda and Nara, 2001; Hubmann et al., 2002; Jundt et al., 2002) . Viral oncoproteins of SV40 (Bocchetta et al., 2003) and HPV16 (Weijzen et al., 2003) induce expression of Notch-1, which participates in SV40- (Bocchetta et al., 2003) and HPV16 (Rangarajan et al., 2001a)-induced transformation, while EBV oncoprotein EBNA2 mimicks active Notch-1 or -2 (Hsieh et al., 1996) . Interestingly, enforced overexpression of constitutively active Notch-1 represses HPV E6 and E7 expression in cervical cancer cell lines (Talora et al., 2002) , suggesting that a negative feedback circuit may exist between these viral oncogenes and Notch-1. This phenomenon appears to be specific for Notch-1. Since these data were obtained using an adenovirusmediated overexpression strategy, it remains uncertain whether spontaneously expressed Notch-1 decreases viral oncoprotein expression in HPV-positive cervical carcinoma cells. Selective loss of Notch-1, with retention of Notch-2, has been described by the same authors in advanced cervical carcinomas (Talora et al., 2002) . If confirmed, these findings may imply that different Notch receptors participate in the early and late stages of tumor progression. Inhibition of Notch expression by antisense retrovirus or pharmacological block of gsecretase have striking antineoplastic effects in Notchexpressing transformed cells in vitro and in xenograft models (Weijzen et al., 2002a; Bocchetta et al., 2003; Weijzen et al., 2003; Weng et al., 2003) . Thus, available evidence suggests that, at least in those malignancies that express intracellular forms of one or more Notch receptors, interruption of Notch signaling may be a promising therapeutic strategy. In one case, namely, the murine epidermis, Notch-1 may function as a tumor suppressor rather than an oncogene (Nicolas et al., 2003) . This may be related to the growth suppressive, p21-mediated effects of Notch-1 in keratinocytes (Rangarajan et al., 2001b) . Similar observations have been made in presenilin-1-deficient mice (Xia et al., 2001) and Notch-1 antisense mice (BJN and LM, unpublished) . How this information applies to human epidermal malignancies is unclear. Our preliminary observations suggest that basal cell carcinomas (BCC) lack activated Notch-1, consistent with the putative tumor suppressor role in the epidermis (BJN and LM, unpublished) . Conversely, malignant melanomas (MM) express the intracellular forms of multiple Notch receptors, particularly Notch-2 and -4 ( Figure 2 , and see (Hendrix et al., 2002) . In the case of BCC, suppression of Notch-1 may be related to growth promotion. The mechanism of this suppression is unknown, but invertebrate data suggest that it may be related to activation of the Wnt/Wingless pathway. In Drosophila, Wingless antagonizes Notch through downstream mediator Disheveled (DshA in mammalian cells). Disheveled physically binds and inactivates the intracellular region of Notch (Axelrod et al., 1996; Blair, 1996) . Overexpression of Wnt ligands in BCC may be triggered by PATCH mutations, which are known to play a key role in BCC pathogenesis (Gailani and Bale, 1999) . In the case of MM, the main effect of Notch signaling appears to be clearly oncogenic, as malignant melanoma cells are exquisitely sensitive to Notch inhibition .
In summary, the overall evidence suggests that, with the possible exception of BCC, Notch signaling inhibition is a viable strategy for the treatment of several solid and hematopoietic tumors. At present, candidates for Notch inhibition strategies that are supported by published data include but are not limited to cervical, endometrial, breast, renal, head and neck squamous and lung carcinomas, pleural mesotheliomas and malignant melanomas. Hematopoietic malignancies include but are not limited to Hodgkin lymphomas, large-cell anaplastic lymphomas, and possibly subsets of CLL and AML. Whether selective Notch-1 activation is a viable strategy in BCC remains to be established.
How is Notch signaling altered in cancer and how does it affect the neoplastic phenotype?
There are two distinct mechanistic questions pertaining to Notch signaling in cancer: (1) How is Notch signaling Figure 2 Immunohistochemistry for Notch receptors in primary lesions of human malignant melanoma. Formalin-fixed, paraffinembedded specimens were cut into 5 mm sections and stained using standard immunoperoxidase methods. Upper panels: low magnification; lower panels; high magnification; insets, negative controls with nonimmune antibodies. This figure shows a representative case out of five, we tested in a pilot study. Note that all four Notch receptors appear to be present in this lesion, and that Notch-4 is especially strong. Nuclear signal was seen in numerous cells for Notch-4 and in a subset of cells for Notch-2 (lower panels). A comprehensive examination of Notch signaling components in malignant melanoma will be described elsewhere Notch signaling as a therapeutic target in cancer BJ Nickoloff et al altered in transformed cells and (2) how does Notch signaling affect the neoplastic phenotype. The mechanism of Notch upregulation in transformed cells has been studied in some detail in human fibroblasts and kidney epithelial cells transformed by expression of telomerase, SV40 oncoproteins and H-RasV12. In these cells, oncogenic Ras enhances Notch-1 protein levels and transcriptional activity, as well as g-secretase component presenilin-1 and Notch ligand Delta-1, primarily by post-transcriptional mechanisms mediated by p38 kinase (Weijzen et al., 2002a) . In these models, as is the case in cervical cancer CaSki cells, Notch silencing or pharmacological inhibition is sufficient to abolish the neoplastic phenotype in vitro and in vivo (Weijzen et al., 2002a; Weijzen et al., 2003) . However, enforced expression of active Notch-1 can only temporarily replace oncogenic Ras, and is unstable in its absence. In Drosophila, where Ras also induces Notch (Carmena et al., 2002) , Notch inhibits some downstream Ras pathways. This suggests that the aberrant Notch-1 activation in Ras-transformed cells represents the pathological counterpart of a physiological feedback mechanism between Ras and Notch. In this model, which is consistent with published evidence (Ikeya and Hayashi, 1999; Ruiz-Hidalgo et al., 1999; Fitzgerald et al., 2000; Berset et al., 2001; Carmena et al., 2002; Shaye and Greenwald, 2002; Weijzen et al., 2002a) excessive Ras activation would trigger aberrant Notch activation, which then mediates key elements of the Ras transformed phenotype but still requires Ras to be stably tolerated by transformed cells. In human mesothelial cells transformed by the SV40 virus in the absence of Ras, an ERK-dependent transcriptional mechanism which required both large and small T oncoproteins is responsible for Notch-1 upregulation (Bocchetta et al., 2003) and in the case of HPV16 oncoproteins E6 and E7, both transcriptional and posttranscriptional mechanisms operate (Weijzen et al., 2003) . In summary, various Ras pathways appear to be upstream of one or more Notch receptors, which may explain the widespread expression of Notch receptors in transformed cells. Ras appears to upregulate Notch signaling via primarily though not exclusively posttranscriptional mechanisms. Additional mechanisms of Notch upregulation may be used by viral and possibly nonviral oncogenes. How does Notch signaling activation participate in transformation or confer a selective advantage to transformed cells? The answer to this question may depend on the specific cell type and Notch receptor(s) considered. Notch receptors have been shown to trigger proliferation signals, survival signals and/or antidifferentiation signals in different cell types. Nuclear migration of Notch-1 appears to be required for the transforming activity of Notch-1 and -2 (Jeffries and . Notch-1 induces cyclin D1 and CDK2 activity, at least in some experimental models (Ronchini and Capobianco, 2001 ). Recent evidence (Nair et al., 2003) indicates that Notch-1 inhibits p53-dependent apoptosis in cervical cancer cells through a mechanism that requires PKB/AKT and sustains the transforming activity of HPV oncoproteins. Constitutive activation of Notch-3 causes lymphomas predominantly via NF-kB activation, mediated by IkB phosphorylation (Bellavia et al., 2000) . Notch-4 requires Ras-mediated ERK and PKB signals for transforming activity (Fitzgerald et al., 2000) . Interestingly, Notch-1 induces expression of Notch-4 (Weijzen et al., 2002a) , which in turn is a well-known proto-oncogene in mammary and salivary glands (Callahan and Raafat, 2001 ). This raises the intriguing possibility that Notch-4 may be a downstream mediator of one or more other Notch isoforms. In T cells, inhibition of differentiation via suppression of pre-T-cell receptor expression has been suggested as a key mechanism of Notch-1-induced lymphomagenesis (Engel and Murre, 2002) . Inhibition of differentiation may be mediated by Notch-induced helix-loop-helix inhibitory transcription factors and, in myeloid cells, by expression of GATA-2 (Kumano et al., 2001) . Consistent with this multiplicity of biochemical mechanisms, different phenotypic effects are seen in different cell types. Hodgkin lymphoma and anaplastic large-cell lymphoma cells, which overexpress Notch-1 and -2, respond to Jagged-1-induced Notch activation with enhanced proliferation (Jundt et al., 2002) . Similarly, Notch inhibition decreases proliferation and anchorage-independent growth in artificially transformed fibroblasts and kidney epithelial cells and in CaSki cervical cancer cells (Weijzen et al., 2002a) . Inhibition of Notch-1 activity by g-secretase inhibition or by an intracellular MAML1 decoy prevents proliferation in pre-T-ALL cells carrying constitutively active Notch-1 (Weng et al., 2003) . However, as we have seen, Notch-1 can both promote and inhibit proliferation in a context-depending manner. Since the antiproliferative effect appears to be mediated mostly by p21 induction (Rangarajan et al., 2001b) , a possible explanation for these contradictory findings may lie in the status of the G1 checkpoint machinery. The formation of cyclin D/CDK4 complexes is dependent upon p21, which binds these complexes but does not inactivate them, unlike CDK2/cyclin E (Cheng et al., 1999) , and actually contributes to CDK4-dependent Rb phosphorylation. Thus, depending on the relative levels of expression of p21, cyclin D1, cyclin E and CDKs 4, 6 and 2, Notch activation may promote cell growth or growth arrest. If the G1 checkpoint and other cell cycle controls are disabled, for example, by overexpression of D cyclins or loss of p16, as is the case in many transformed cells, Notch-1-mediated induction of p21 may be unable to cause growth arrest. It is interesting that in many cases, Notch-1 and -2 have been shown to cooperate with viral oncogenes that inactivate Rb, and thus largely disable the G1 checkpoint. Inhibition of apoptosis by Notch-1 has been seen in several models Shelly et al., 1999; Zlobin et al., 2000; Rangarajan et al., 2001a) . Induction of NF-kB (Cheng et al., 2001) , inhibition of JNK Zecchini et al., 1999) , inactivation of Nur77 (Jehn et al., 1999) and activation of PKB/AKT (Rangarajan et al., 2001a) have been suggested to mediate these survival signals. Notch-3 can induce antiapoptotic protein c-FLIP via ERK (Wang et al., 2002) . In this context, even induction of p21 may act as a survival signal by slowing growth and thus reducing the sensitivity to DNA damage (Gartel and Tyner, 2002) . Finally, there is evidence that Notch-1, Notch-4 and Delta-4 may collaborate in angiogenesis (Xue et al., 1999; Krebs et al., 2000a; Mailhos et al., 2001; Liu et al., 2003) , but constitutively active Notch-4 can inhibit angiogenesis (Leong et al., 2002) . In summary, Notch activation in transformed cells can induce proliferation and/or survival or inhibit differentiation, and different combinations of these mechanisms could operate in different cell types. The role of Notch signaling in angiogenesis deserves further investigation. Some Notch effectors have been identified and it is very likely that more remain to be identified.
Pharmacological and genetic strategies to manipulate Notch signaling for therapeutic purposes
A number of genetic and pharmacological strategies are available to block or silence Notch signaling (Figure 1 ). Specific strategies that selectively target individual Notch receptors include antisense (Garces et al., 1997; Shelly et al., 1999; Yasutomo et al., 2000; Weijzen et al., 2002a; Weijzen et al., 2003) , RNA interference (LM, unpublished) and monoclonal antibodies (Yasutomo et al., 2000) , while pharmacological small-molecule inhibitors of individual Notch receptors have not been described yet. Nonselective strategies include soluble receptor decoys that act by sequestering Notch ligands (Garces et al., 1997; Nickoloff et al., 2002) and pharmacological inhibitors of gamma-secretase (Weijzen et al., 2002a) , which prevent the second ligand-induced proteolytic cleavage of Notch receptors. These agents simultaneously target all Notch receptors (Mizutani et al., 2001) . TACE inhibitors and fucosyltransferase or Fringe glycosyltransferase inhibitors could theoretically be used for the same purpose. In some Ras-transformed cells, it is conceivable that specific inhibitors of Ras downstream kinases could inhibit Notch activation (Weijzen et al., 2002a; Bocchetta et al., 2003) . A MAML1 decoy has been used in cell culture (Weng et al., 2003) , showing that this is another potential target point to inhibit Notch signaling with small molecules. There are advantages and disadvantages to each of these strategies. The nonselective agents are likely to have more widespread side effects. On the other hand, since tumor cells often express more than one Notch receptor (see Figure 2) , these agents may be a more practical way to proceed towards clinical development, compared to parallel, selective targeting of multiple receptors. Oligopeptide Notch agonists derived from natural ligands have been described (Li et al., 1998; Nickoloff et al., 2002) and may be useful in specific settings, such as dermatology, including dermatological oncology and immunoregulation (e.g. ex vivo DC generation).
Potential toxicity targets: the physiology of Notch signaling in mammals
The potential advantage of Notch inhibitors as antineoplastic agents stems from the fact that Notch signaling is at the crux of multiple survival and proliferation pathways. Precisely for this reason, understanding the possible side effects and target tissues of Notch-targeted therapeutics is an indispensable step in the development of these agents. Mouse 'knockout' models of Jagged-1, Notch-1, and -2 are embryonically or perinatally lethal, while the Notch-4 knockout has no overt phenotype but indicates that Notch-1 and -4 cooperate in angiogenesis and vascular remodeling (Swiatek et al., 1994; Xue et al., 1999; Krebs et al., 2000b) . This suggests that the developmental functions of these Notch receptors are not entirely overlapping, but Notch-4 is dispensable for development. However, the Notch-1 antisense mouse is viable and fertile (Cheng et al., 2001 ) (BAO and LM, in preparation), indicating that postnatal inhibition of Notch-1 signaling can be tolerated. Notch-3 has been described as an inhibitor of Notch-1 signaling, which is necessary for the development of the endocrine pancreas (Apelqvist et al., 1999; Beatus et al., 1999) . Mutations in the human Notch 3 gene cause the vascular stroke and dementia syndrome CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) characterized by degeneration of vascular smooth muscle cells and multiple small brain infarcts (Joutel et al., 1996) , suggesting an indispensable role in maintaining the survival of some arterial smooth muscle cells. Owing to the therapeutic focus of this article, we will focus on nondevelopmental, postnatal roles of Notch signaling in mammals. These are incompletely understood, but have been studied most extensively in the immune and hematopoietc systems as well as the epidermis.
Immune and hematopoietc systems
The role of Notch signaling in T-cell development in the thymus has been intensely studied. Most of the available information is related to Notch-1, although at least three Notch receptors are expressed in the mammalian thymus (Felli et al., 1999) . Notch-1 appears to be necessary very early during lymphopoiesis, to determine the choice between B-and T-lineage (Pui et al., 1999; Allman et al., 2002; Izon et al., 2002) . In the thymus, Notch-1 appears to be required for expansion of early double-negative precursors (Radtke et al., 1999) . Similarly, extrathymic development of intestinal mucosa T-cells requires Notch-1 . The possible role of Notch signaling in CD4 versus CD8 cell fate determination, specifically to favor the CD8 lineage, has been hotly debated Osborne, 2000; Anderson et al., 2001) . Using reaggregate cultures, antisense Notch-1 and a Notch-1 blocking antibody, Yasutomo et al. (2000) concluded that Notch-1 is required not for the lineage choice itself, but for complete development of CD8 cells after the choice, which is instead affected by strength and duration of the TCR signal. Other authors have suggested that Notch-1 is required for the maturation of both CD4 and CD8 cells (Deftos et al., 2000) . On the other hand, Wolfer et al. (2001) failed to show an effect of Notch-1 beyond the double-negative stage. More recently, Fowlkes and Robey (2002) have confirmed in two different transgenic models that expression of constitutively active Notch-1 does favor the CD8 lineage development in a way that depends on MHC I and II.
Little is known on the possible role of Notch signaling in mature, peripheral T and B cells during an active immune response. This field is being actively investigated in several laboratories. Another immunocyte that appears to require Notch-1 for its development is the myeloid dendritic cell (DC). Using an antisense Notch-1 mouse developed by LM Cheng et al. (2001) have shown that hematopoietic precursors of these mice are deficient in their ability to mature to DC. This was shown to be due to decreased expression of several NF-kB subunits. Interestingly, B-cell proliferation in response to LPS was also impaired in these mice. Weijzen et al. (2002b) have shown that human monocyte maturation into DC can be enhanced by treatment with a soluble Notch ligand. This is consistent with data by Ohishi et al. (2001) that indicate that immobilized Notch ligand Delta-1 blocks monocyte differentiation into macrophages but permits differentiation into DC, and suggests that in some cases a Notch signal may be required for differentiation towards a specific fate not just by blocking alternative fates, but also by promoting certain cell fates. Of potential medical interest is the expression of Notch-1, -2 and -3 in synoviocytes of patients with rheumatoid arthritis and osteoarthritis, where one or more Notch receptors may participate in TNF-ainduced proliferation Nakazawa et al., 2001) .
The role of Notch signaling in hematopoiesis has been extensively investigated (Ohishi et al., 2002b) . Evidence accumulated over the past 9 years indicates that CD34 þ cells express Notch-1 and Notch-2, bone marrow stroma cells express Notch ligands, and Notch signaling, together with cytokines and hematopoietic growth factors, participates in the cell fate choice between selfrenewal and differentiation in hematopoietic precursors. Expression of constitutively active Notch-1 immortalizes hematopoietic precursors and establishes continuously growing cells that retain the ability to differentiate towards either lymphoid or myeloid lineages under the influence of specific cytokines (Varnum-Finney et al., 2000) . Exposure of sorted murine hematopoietic precursors to cell-associated or immobilized Jagged-1 increases the number of cells with primitive hematopoietic precursor phenotype (Varnum-Finney et al., 1998) . Similarly, long-term exposure to Delta-1 enhances marrow and thymus repopulating ability of human CD34( þ )CD38(À) cord blood cells (Ohishi et al., 2002a) . In combination with cytokines, Delta-1 causes a large increase in the number of murine hematopoietic cells capable of reconstitute lymphoid and myeloid lineages (Varnum-Finney et al., 2003) .
Overall, these data suggest that a Jagged-1-or Delta-1-mediated Notch signal enhances the self-renewal ability of multipotent hematopoietic precursor cells, and could therefore be useful for in vitro expansion of hematopoietic cells prior to reinfusion into patients. Modulating the Notch signal with cytokine combinations may be used to generate larger numbers of specific populations of cells ex vivo.
The mammalian epidermis
The role of Notch signaling in the mammalian epidermis appears to be somewhat different from its role in the immune and hematopoietic systems. The most undifferentiated basal cells in the human epidermis do not respond to Notch signals. Instead, they express high levels of Delta-1 and prevent Notch-1 activation via Delta-Delta homotypic interactions (Lowell et al., 2000) . These cells are capable of activating Notch-1 in neighboring cells, which are induced to undergo a few rounds of proliferatation followed by differentiation. Lowell et al. (2000) propose that a Notch signal in the context of the epidermis triggers differentiation rather than preventing it. In addition, they propose that Delta-1 may promote cohesion of epidermal stem cells by homotypic interactions, and prevent them from entering the 'transit-amplifying' compartment that preludes to differentiation. In murine keratinocytes, constitutively active Notch-1 induces p21 expression at the transcriptional level, through CBF-1 sites in the p21 promoter (Rangarajan et al., 2001b) , and causes exit from the cell cycle. At the same time, Notch-1 induces the expression of early differentiation markers and prevents the expression of late differentiation markers. Taken together, these observations suggest that a Notch-1 signal guides the early stages of keratinocyte differentiation, including growth arrest, perhaps preceded by a few rounds of replication, and expression of early differentiation markers. The antiproliferative role of Notch-1 in the murine epidermis has been recently confirmed in targeted inducible KO mice (Nicolas et al., 2003) , where loss of Notch-1 favors keratinocyte proliferation and indirectly, tumorigenesis. Similar observations have been made in Notch-1 antisense mice (BJN and LM, unpublished) . Reduced or deficient expression of Notch in actively proliferating, psoriatic epidermis had been previously described . The role of Notch signaling in epidermopoiesis has been studied in detail by Nickoloff et al. (2002) . These authors have demonstrated that all four Notch receptors are expressed in the human skin. Notch-2 appears to be confined to basal layers and Notch-1 is expressed throughout but decreases in the most superficial layers, while Notch-3 and -4 are expressed predominantly in suprabasal layers immediately below the stratum corneum. Delta-1 is expressed in basal layers as previously described, while Jagged-1 is expressed throughout the epidermis. Using epidermal equivalents in vitro, these authors demonstrated that a soluble Notch ligand is sufficient to trigger complete keratinocyte differentiation up to and including cornification. Notch signaling is necessary for cornification induced by a liquid-water interface, because the process is aborted in the presence of a Notch decoy protein. A possible mechanism of these effects was described : soluble Jagged-1 peptides induce rapid and transient activation of NF-kB, followed by induction of PPARg, which in turn neutralizes NF-kB. Both NF-kB and PPAR transcription factors are thought to be necessary for keratinocyte differentiation Rosenfield et al., 2000) . Which of the Notch isoforms is responsible for these effects is still unclear, as is the mechanism of direct activation of NF-kB by Jagged ligands. Recent evidence suggests that Notch-1 in keratinocytes also induces IKKa , which is required for keratinocyte differentiation independently of NF-kB (Hu et al., 2001) . Taken together, these observations clearly show that in the context of the mammalian epidermis, Notch signaling induces differentiation and is required for it. A coordinated effect of all four Notch receptors may be necessary for epidermopoiesis.
Other organs and tissues
There is some evidence that Notch signaling may participate in regeneration of rat hepatocytes, which are induced to proliferate and differentiate by stromal cells expressing Jagged-1 (Mizuguchi et al., 2001 ). This may suggest a possible use of Notch agonists to aid liver regeneration. A more complex role may be played by Notch signaling in the intestinal epithelium. Yang et al (Yang et al., 2001) , suggest that Delta-Notch signaling via HES1 promotes the differentiation of enterocytes from intestinal 'stem cells' while inhibiting the differentiation of secretory cells (Paneth, enteroendocrine and goblet cells). Thus, in the intestinal mucosa Notch signaling may have a classical 'lateral inhibition' function in the fate choice between the enterocyte lineage and the secretory lineage, and a prodifferentiation 'instructive' role in enterocyte development. Sequential Notch receptor activation has been suggested to occur during spermatogenesis (Mori et al., 2003) and in ovarian follicles (Johnson et al., 2001) . There is strong evidence that Notch signaling participates in mammalian brain development, primarily inhibiting neuronal differentiation and allowing/ promoting glial differentiation (Morrison et al., 2000; Grandbarbe et al., 2003) . Expression of Notch in the adult brain has been described (Berezovska et al., 1998; Berezovska et al., 1999) , but the postnatal neurological functions of Notch signaling remain largely unexplored.
In summary, there is evidence that Notch signaling participates in postnatal cell fate determination in numerous tissues. In some tissues, Notch activation maintains relatively undifferentiated pools of cells (e.g. bone marrow, intestinal epithelium), while in other cell types, Notch signaling under physiological conditions may promote rather than inhibit differentiation (e.g. epidermis, adipocytes). In these cells, it is likely that Notch activation triggers transient survival and proliferation signals (e.g. cyclin D1, PKB, NF-kB,) while temporarily inhibiting terminal differentiation. This could be followed in some cases by growth arrest signals (e.g. p21) and differentiation signals (e.g. PPARs). Whether differentiation processes can be driven by individual Notch receptors or require the concerted, sequential action of multiple Notch receptors remains to be established.
Future directions
Available evidence strongly indicates that Notch signaling may be frequently deregulated in cancer, and Notch inhibition may be a novel therapeutic strategy. However, much remains to be understood. First, different Notch isoforms are expressed in different cancers. However, it is unclear whether the four human Notch isoforms have common effectors in cancer and what is the functional relationship between Notch isoforms. While all Notch receptors target CBF-1, their effects may be different depending on the specific complexes formed (Beatus et al., 2001 ). Notch-3 may antagonize Notch-1 , while Notch-2 has been suggested to inhibit Notch-1 and -3 effects (Shimizu et al., 2002) . Conversely, Notch-1 can induce Notch-4 (Weijzen et al., 2002a) , and may cooperate with it (Krebs et al., 2000) . Little is known about the different downstream targets of the various Notch isoforms. Second, the relationship between physiological Notch signaling and Notch signaling in cancer needs to be clarified. It is likely that Notch effects in transformed cells result from quantitatively excessive or abnormally sustained Notch activation, which may not recapitulate physiological signaling. This raises the possibility that some downstream effectors may be only used by Notch receptors in transformed cells. An obvious question is whether therapeutically effective Notch inhibition can be accomplished in vivo without unacceptable toxicity. This is a common concern when manipulating key cell fate mediators. SV40-immortalized fibroblasts, unlike their Ras-transformed counterparts, are not sensitive to Notch inhibition (Weijzen et al., 2002a) . Antisense Notch-1 transgenic mice are viable and fertile, indicating that Notch inhibition can be compatible with near-normal life. Yet, there is little doubt that inhibition of Notch signaling, whether accomplished by genetic or pharmacological means, will have some side effects. The nature and extent of these effects will only be determined in well-designed pharmacological studies. However, most effective cancer agents have significant toxicity, which does not prevent their clinical use. Systemic adverse effects can be ameliorated by 'smart' delivery strategies that use targeted local release of antineoplastic agents. While many questions remain unanswered, the role of Notch signaling in cancer pathogenesis and treatment deserves further investigation. The results of these studies may include new classes of broadly effective antineoplastic agents.
